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ABSTRACT
Introduction: Falls are the leading cause of accident-
related mortality in older adults. Injurious falls are
associated with functional decline, disability, healthcare
utilisation and significant National Health Service
(NHS)-related costs. The evidence base for
multifactorial or exercise interventions reducing
fractures in the general population is weak. This
protocol describes a large-scale UK trial investigating
the clinical and cost-effectiveness of alternative falls
prevention interventions targeted at community
dwelling older adults.
Methods and analysis: A three-arm, pragmatic,
cluster randomised controlled trial, conducted within
primary care in England, UK. Sixty-three general
practices will be randomised to deliver one of three
falls prevention interventions: (1) advice only; (2)
advice with exercise; or (3) advice with multifactorial
falls prevention (MFFP). We aim to recruit over 9000
community-dwelling adults aged 70 and above.
Practices randomised to deliver advice will mail out
advice booklets. Practices randomised to deliver ‘active’
interventions, either exercise or MFFP, send all trial
participants the advice booklet and a screening survey
to identify participants with a history of falling or
balance problems. Onward referral to ‘active’
intervention will be based on falls risk determined from
balance screen. The primary outcome is peripheral
fracture; secondary outcomes include number with at
least one fracture, falls, mortality, quality of life and
health service resource use at 18 months, captured
using self-report and routine healthcare activity data.
Ethics and dissemination: The study protocol has
approval from the National Research Ethics Service
(REC reference 10/H0401/36; Protocol V.3.1, 21/May/
2013). User groups and patient representatives were
consulted to inform trial design. Results will be
reported at conferences and in peer-reviewed
publications. A patient-friendly summary of trial
findings will be published on the prevention of falls
injury trial (PreFIT) website. This protocol adheres to
the recommended SPIRIT Checklist. Amendments will
be reported to relevant regulatory parties.
Trial registration number: ISRCTN 71002650; Pre-
results.
INTRODUCTION
Falls and fall-related fractures are a major
public health burden for individuals and
society. Falls are associated with loss of inde-
pendence, functional decline and are a con-
tributing reason for subsequent admission to
a long-term care.1 The majority of falls result
in minor injury and pain, but are sometimes
coupled with a fear of falling and loss of con-
fidence in mobility. Falls, however, can also
lead to serious injury, with fracture and hos-
pitalisation occurring in 5% of community
dwelling older adults with a history of
falling.2 The financial burden associated with
injurious falls is staggering: direct healthcare
and associated social care costs in the UK
have been estimated at £2 billion per annum,
mostly associated with hip fracture.3 Costs
arise from hospital admission and clinical
care associated with treatment of injurious
falls and fractures. Mortality is high in
people who sustain fracture. For hip fracture,
10% die within 30 days and one-third die
within 12 months.4 Demographic change
means that injurious falls in older people
may become increasingly common.
Over the past 30 years, much effort has
been directed towards the implementation
and evaluation of fall prevention strategies.
Falls have a multifactorial aetiology, with
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many putative risk factors identified.5 The major risk
factors are diverse, and potentially modifiable, including
impairments of gait and balance, visual impairments,
syncope and cardiac rhythm abnormalities, polyphar-
macy and certain classes of medication, comorbidity,
foot disorders and environmental hazards. Early clinical
trials of assessment and treatment of multiple risk
factors, termed multifactorial falls strategies, were very
promising, suggesting beneficial effect in falls reduction
when compared to usual care. These early trials pro-
vided the foundation for the mandatory establishment
of secondary prevention in the UK, through the intro-
duction of falls services to undertake multifactorial falls
prevention (MFFP) interventions on people with a
history of falling.6 These trials did not, however, system-
atically examine the effect of interventions on injurious
falls. To justify widespread introduction of services for
the primary prevention of falls, evidence is needed that
these interventions reduce injurious falls. Multifactorial
risk assessment, followed by targeted treatment of indi-
vidual risk factors, is currently the mainstay for falls pre-
vention in the UK, supported by clinical organisations
(American Geriatric Society/British Geriatric Society)
and the UK National Institute for Health and Clinical
Excellence.7 Falls services have been widely introduced
throughout the UK National Health Service (NHS),
although structure and process evaluation revealed con-
siderable variability in service design, models of delivery
and professional skill mix.8 9
Numerous trials have been conducted to investigate
the efficacy of falls prevention initiatives; a systematic
review included 159 trials of different falls prevention
strategies, many of which were complex interventions.10
Certain exercise programmes, in particular, those focus-
ing on individualised and progressive gait, strength and
balance retraining, have been shown to reduce rate of
falls by approximately 25%.10 Challenges include exercise
adherence, however, strength and balance interventions
may be a cost-effective strategy. Worryingly, several system-
atic reviews have found mixed evidence for multifactorial
fall risk assessment and intervention on outcomes of rate
of falls and fall-related injuries. Gates et al11 suggested
that multifactorial interventions may reduce the rate of
falls without affecting the number of fallers (falls risk), a
finding confirmed in an updated Cochrane review.10
These systematic reviews identified methodological
deficiencies in existing trials, with many studies being
underpowered and lacking robust data on important
outcomes, including quality of life, fracture, costs of
intervention and cost-effectiveness. Of those reviewed,
only 11 of 40 published trials of multifactorial interven-
tions included fracture outcomes, despite serious injury
causing the greatest burden to patients and contributing
to resource use.10 No trials have been sufficiently prag-
matic to estimate the impact of fall screening and inter-
vention at a population level.
Given the widespread introduction of falls services in
the UK and current recommendations for MFFP in
certain populations, adequately powered studies are
urgently required to investigate the effectiveness of such
initiatives on clinical and patient-reported outcomes.
This cluster randomised controlled trial is designed to
compare the effectiveness of alternative strategies to




The overall aim is to determine the comparative effect-
iveness and cost-effectiveness of three primary care fall
prevention interventions: advice alone, advice supple-
mented with either exercise or MFFP, in adults aged
70 years and above, on outcomes of fracture, falls and
quality of life. Specific trial objectives are to: (A) esti-
mate the effectiveness of intervention in community-
dwelling people of different age, frailty status, gender
and falls history; (B) measure the uptake of and reten-
tion to exercise and MFFP (active interventions) and the
impact these have on effectiveness; and (C) to assess the
relative costs of each intervention and to determine the
most cost-effective approach.
Trial design and setting
Core trial information is presented in table 1 (WHO
Trial Registration Data Set). This study is a three-arm
pragmatic cluster-randomised controlled trial with paral-
lel economic analysis. The trial design framework is
superiority rather than equivalence or exploratory. The
trial is currently running in primary care; a minimum of
9 000 participants will be recruited from 63 general prac-
tices across England. Recruitment is underway in differ-
ent English regions selected to ensure our population is
geographically representative and includes extremes of
latitude. We are recruiting in the South-West (Devon),
Central (West Midlands, Cambridgeshire) and Northern
England (Newcastle). Urban and rural practices will be
recruited with support provided by existing Primary
Care Research Networks (PCRN) and Comprehensive
Local Research Networks (CLRN). A pilot study was
undertaken in the Devon Region to assess operational
futility, namely to assess the feasibility of setting up
recruitment, interventions and referral processes. The
Trial Steering Committee (TSC) and funder reviewed
pilot study findings before the main trial was launched.
Eligibility criteria—cluster level
Practice eligibility: General practices are eligible to partici-
pate if they are located in an English region with infra-
structure to support the trial. Additional eligibility
criteria include agreement to adhere to a predeter-
mined active treatment pathway (exercise or MFFP) and
technical capacity to undertake electronic searching to
identify a suitable population base for sample selection.
Modest reimbursement is provided to cover practice
time and postage.
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Eligibility criteria—participant level
Participant eligibility: Community-dwelling older adults,
defined as aged 70 years or above, resident in the com-
munity or in sheltered housing. Exclusions include
those in long-term residential or nursing care and those
with terminal illness or expected shortened lifespan,
defined as less than 6 months, as determined by the
general practitioner (GP). No specific restrictions or
exclusions by sex, cognitive functioning, comorbidity or
falls history apply.
Participant recruitment and consent
We seek to recruit 150 participants (range 129–179)
from each general practice (figure 1). Practices search
their electronic database to identify a random sample of
400 older adults aged 70 years and above. After removal
of exclusions, practices then mail an invitation pack
which contains a participant information sheet, baseline
questionnaire and consent form. With an estimated
enrolment rate of 35%–40% this yields 140–160
recruited participants per practice (figure 2). Informed
consent is sought from each participant for access to
medical records and routine primary and secondary
care data held by the UK NHS Health and Social Care
Information Centre. Patient-specific data are only col-
lected on those providing consent.
Allocation sequence generation and randomisation
The unit of cluster randomisation is the general practice
(figure 2). Once 150 participants are recruited from
three GP practices, practices are then randomised in a
block of three to ensure that concealment of the alloca-
tion sequence is maintained. Randomisation is based on
a computer-generated randomisation algorithm held
and controlled centrally within the trials unit by an inde-
pendent programmer. Once informed of practice alloca-
tion, trial administrators then implement screening
procedures and research staff plan intervention delivery
with local site investigators.
Table 1 WHO Trial Registration Data Set
Data category Information
Primary registry and trial
identifying number
ISRCTN 71002650: Prevention of fall injury trial (PreFIT)
Date of registration in primary
registry
13/04/2010
Secondary identifying numbers Health Technology Assessment (HTA)
Source of monetary or material
support
National Institute for Health Research (NIHR) HTA
Primary sponsor University of Warwick
Secondary sponsor Not applicable
Contact for public queries prefit@warwick.ac.uk
Contact for scientific queries Dr Julie Bruce, Warwick Clinical Trials Unit, University of Warwick
Public title PreFIT
Scientific title PreFIT a parallel group cluster randomised controlled trial and economic evaluation
Countries of recruitment UK
Health condition or problem
studied
Falls and fractures in older adults
Interventions Advice only: Age UK leaflet
Comparator 1: Exercise: PreFIT-Otago Home Exercise Programme
Comparator 2: Multifactorial falls prevention assessment (MFFP)
Key inclusion and exclusion
criteria
Age: 70 years or over, no upper age restriction
Sex: Male or female
Inclusion: Any comorbidity, resident in the community or sheltered housing
Exclusion: Those resident in long-term residential or nursing care, those with terminal
illness or expected shortened life span defined as less than 6 months, as determined by
general practitioner. No restrictions by cognitive functioning, comorbidity or falls history
apply
Study type Interventional
Allocation: randomised; cluster assignment
Primary purpose: prevention, setting primary care
Phase III
Date of first enrolment October 2011
Target sample size Over 9000
Recruitment status Recruiting
Primary outcome Peripheral fracture
Key secondary outcomes Falls, health-related quality of life, mortality, healthcare resource use
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Blinding
The Consolidating Standards for Reporting Clinical
Trials (CONSORT) Statement 2010 and subsequent
update extension to cluster randomised trials recom-
mend transparent reporting of blinding status in relation
to participants, data analysts, outcome assessors and
intervention.12 At the invitation stage, patients are con-
sented for data collection and follow-up; they are
informed that their GP may contact them with another
short questionnaire asking about balance and function,
which will be used to determine further advice. At this
stage, participants are blinded to treatment options. At
the referral to treatment stage, participants are also
blinded to other alternate treatment options. Owing to
the nature of the prevention of falls injury trial (PreFIT)
‘active’ interventions, it is not possible to blind therapists
or services delivering exercise or MFFP. Blinding of data
analysts and outcome assessors is fully achieved. Senior
investigators are blinded to treatment allocation for the
duration of the conduct of the trial. The statistical ana-
lysis plan was developed by the study team and approved
by external monitoring committees. Data cleaning and
analysis of the primary outcome will be conducted by a
trial statistician unaware of treatment allocation. Data
entry and processes to ensure data quality will be under-




All trial participants, across all three intervention arms,
receive the ‘Staying Steady’ booklet by post. This 29-page
booklet, produced and published by Age UK, contains
clear information about improving strength and
balance, information about eyesight, hearing, managing
medications, the home environment and dealing with
advice on fear of falling. Contact numbers and websites
for different national help organisations are provided.
This colourful information booklet was selected for use
because of the positive emphasis on remaining steady
and active rather than focus on falls per se. Practices
allocated to the ‘Advice only’ arm deliver no further
planned intervention and are not actively screened for
balance problems.
Screening and referral to active intervention
A primary care screening approach is used whereby
decision about onward referral of participants to exer-
cise or MFFP is determined from a 1-page short self-
complete balance and falls screening survey. Balance
screening surveys are mailed from and returned to
general practices. The balance screen includes questions
on falls history and current balance, based on previous
research predicting thresholds for falls.13 Participants
reporting balance problems whilst walking, dressing or
with daily activities and those reporting one or more fall
in the previous 12 months are categorised as being at
intermediate or high risk of falling. These participants
are then offered the opportunity to attend for further
assessment and treatment, either exercise or MFFP,
depending on cluster allocation.
Exercise arm
The PreFIT exercise intervention is based on the Otago
Home Exercise Programme (OEP), which targets lower
limb strength, balance retraining and walking.14 15
Figure 1 Flow diagram of cluster. MFFP, multifactorial falls prevention; PreFIT, prevention of falls injury trial.
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Participants eligible for the exercise intervention are
invited to attend for baseline assessment, comprising a
chair-stand test and four-test balance scale. The OEP is
an individually prescribed, progressive exercise pro-
gramme which can be administered either at home or
via group classes by a PreFIT-trained physiotherapist or
exercise instructor. The PreFIT-OEP contains five
warm-up exercises, five strength exercises with/without
ankle cuff weights, and 12 balance retraining exercises.
Optimal duration of the PreFIT OEP is 6 months, with a
recommended minimum of three face-to-face contacts
with telephone support by a trained therapist. Therapists
have the flexibility to deliver the intervention in group
or individual sessions, depending on their local service
configuration. Exercise adherence will be reported as
number of participants who fully or partially complete
the exercise programme.
MFFP arm, with or without exercise
The PreFIT MFFP is based on an existing evidence-
based MFFP intervention,16 with modifications to align
with current UK recommendations for falls risk assess-
ment and treatment pathways.6 17 The following risk
factors are assessed on all patients referred for MFFP:
comprehensive falls history interview; identification of
red flags; gait and balance assessment; consideration of
fear of falling; postural hypotension and arrhythmia
screen; medication screening and GP-led review of
psychotropic and culprit drugs; Snellen visual acuity test;
feet and footwear assessment and home environment
screening interview. The falls assessment is conducted by
a trained healthcare practitioner or falls team, followed
by recommendations or further onward referral to
another service where indicated. The assessment consists
of examinations performed within the general practice,
the home, community or general hospital by a practice
nurse or equivalent registered healthcare professional,
or by a community or hospital-based falls team. The
location of the falls assessment will vary due to the prag-
matic trial design. Standardised treatment recommenda-
tions are linked to each of the risk factors. For example,
participants receiving MFFP who have impaired gait and
balance or fear of falling are eligible for referral to
PreFIT OEP intervention. This is consistent with all
models of MFFP delivery, is purposeful and does not
represent contamination between the intervention arms.
Detailed description of PreFIT active interventions
including the selection of MFFP risk factors, develop-
ment of exercise and MFFP manuals, testing of interven-
tions and processes for training of healthcare
professionals and quality assurance will be reported in a
separately, as per recommended guidance for trial inter-
vention description and replication.18
Cotreatments
Trial participants are free to seek management of falls
and any other related or unrelated medical conditions
during the course of the trial. We place no restriction on
other agencies contacting participants about fall preven-
tion strategies. We record all health service resource use
and these will be reported as a trial outcome. At trial
closure, participants will continue with usual healthcare,
no further ancillary care is provided beyond that imme-
diately required for the proper and safe conduct of the
trial.
Intervention fidelity checks and process evaluation
We will report intervention fidelity, process and compli-
ance using a mixture of structured treatment records
and observation during quality assurance visits. The trial
treatment record includes details on dose and mode of
delivery of the major elements of the MFFP and exercise
interventions, as well as the grade and type of staff
involved with the delivery.
Outcomes
Primary outcome
The primary outcome is peripheral fracture, expressed
as the fracture rate per person per months of observa-
tion over 18 months after randomisation of the general
practice. Peripheral fracture, defined according to an
internationally agreed definition,19 includes any fracture
in the appendicular skeleton, thus limbs, limb girdles,
cranial and facial bones. Compression fractures within
the vertebral column will be excluded from the primary
outcome. Fracture data will be obtained from three
Figure 2 Schedule of enrolment and interventions per
cluster (SPIRIT Template). *Active interventions of exercise
and MFFP offered to subgroups of participants at intermediate
or high risk of falling. Low risk participants in active arms
receive advice leaflet only.
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sources: Hospital Episode Statistics (HES), self-report
from patients and a targeted search of GP records. The
Health and Social Care Information Centre (HSCIC) is
the national body for mandatory data collection from
hospitals in England; HES data on the length, type and
reasons for all NHS inpatient hospital admissions, acci-
dent and emergency (A&E) and outpatient clinic atten-
dances will be obtained for trial participants. These data
sets include private patients treated in NHS hospitals.
Searches of these HES data sets will be undertaken to
identify relevant International Classification of Diseases
V.10 codes (ICD-10) diagnosis and treatment codes
(table 2). Fracture data will also be obtained from self-
report from follow-up questionnaires at 4, 8, 12 and
18 months and a targeted search of general practice
records (using READ Codes and free-text). Self-reported
fracture is captured using questions about falls-related
broken bones collected at baseline and follow-up.
Participants reporting any broken bone are contacted by
post and telephone interview to collate additional infor-
mation on fracture site, date and hospital treatment.
Although no single data set can be considered as 100%
accurate and timely, any ICD-10 fracture diagnosis
reported on HES in-patient data will be accepted as a
confirmed event (figure 3). A triangulation approach
will be used: any HES A&E fracture code, any self-
reported fracture or any fracture from GP Read Code
screening will be investigated further by undertaking a
full search within GP-held patient records for the rele-
vant time period (eg, X-ray reports, hospital discharge
or clinic letters). Data sources will be cross-checked
against other sources. A data validation protocol,
approved by external trial committees, will be used to
determine suspected and confirmed fracture events. A
clinical review panel, blinded to intervention allocation,
will review all data sources for any suspected/uncon-
firmed fracture. In the event that HES data are not avail-
able, the trial will recourse to a protocol based on
self-report and GP records.
Secondary outcomes and baseline data
Secondary outcomes include number of patients with at
least one fracture, falls, mortality, health-related quality
of life and resource use. These outcomes will be cap-
tured also by postal questionnaires administered at base-
line, 4, 8, 12 and 18 months (table 2). Outcome
measures will be collected at baseline, with additional
information on demographic characteristics, self-
reported comorbidity and a brief frailty screen. Pilot
data collection instruments and balance screeners were
developed with input and feedback from patient repre-
sentatives within the target age group; instruments were
revised accordingly.
Falls data collection
Falls definition: we will use an internationally agreed def-
inition of a fall as being an event in which the partici-
pant comes to rest on the ground, floor or other lower
level.19 20 This item is phrased as: “in the last 12 months,
have you had any fall including a slip or trip; following which
you have come to rest on the ground, floor or lower level?”. The
reference timeframe is altered according to timing of
Table 2 Overview of data collection and outcome measures
Variable Data source and instrument Time point (months)
Primary outcome
Peripheral fracture
HES inpatient (ICD-10, OPCS codes)
HES A&E






CRF—Falls in previous 12 months




4, 8, 12, 18
0–12 months
Health-related quality of life CRF—Short-Form 12 (V.2)
CRF—EuroQol EQ-5D
0, 4, 8, 12, 18
0, 4, 8, 12, 18





Height/weight (BMI) CRF 0
Mobility CRF 0, 4, 8, 12, 18
Frailty CRF—Strawbridge21 0, 18
Clock drawing test CRF—Shua-Haim22 0
Healthcare resource use CRF—Primary care consultations
CRF—Secondary care attendances
(NHS and private)
4, 8, 12, 18
A&E, accident & emergency; BMI, body mass index; CRF, case record form; CTV, Clinical Terms Version; GP, general practitioner; HES,
Hospital Episode Statistics; ICD, International Classification of Diseases; NHS, National Health Service; OPCS, Office of Population Census &
Surveys.
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follow-up such that the reporting period covers the time
since the last follow-up.
Falls recording: Two approaches will be used to
capture falls: retrospective self-report (for a reporting
period of the preceding months) for each individual
over the entire follow-up period and prospective
monthly falls diaries. All participants complete a pro-
spective falls diary on a daily basis for a 4-month
period during the first year. The collection of falls data
by diary is a substantial effort for participants and is
resource intensive. Because the analysis of falls data
requires substantially fewer participants than the frac-
ture outcome, we designed a strategy of identifying a
random subsample of participants to provide diary data
in each 4-month period of follow-up, up to 12 months.
A computer-generated programme randomly allocates
participants to their prospective data collection time
point, thus 0–4 months, 4–8 months or 8–12 months
from randomisation. Random sampling is without
replacement. Prepaid postal diaries are completed each
day then returned using to the trial office at the end
of each month. Diary data will be used in two ways. We
will examine biases in the retrospective fall data report-
ing, using the fall diary as the gold standard to deter-
mine whether the retrospective report can be
considered a robust data source. In addition, we will
model falls data using the diary reports for the first
year of follow-up.
Mobility/ADLs: questions on difficulties balancing on a
level surface, ability to walk outside of the house, and
average time spent walking will be included at baseline
and each subsequent follow-up.
Frailty: A 16-item frailty questionnaire is included at
baseline and 18 months.21 This measure is weighted
towards sensory assessment.
Cognitive ability: A clock-drawing test is included at
baseline as a cognitive screening. We will use a six-
point scoring system, based on the visual-spatial aspects
and correct denotation of time by the hand of the
clock.22
Health-related quality of life
Health-related quality of life is captured using the
Short-Form 12 and EuroQol 5D. The SF-12 provides a
measure of physical function, engagement in usual activ-
ities and mental functioning.23 The EQ5D is a standar-
dised measure of self-reported health-related quality of
life which includes five domains: mobility, self-care,
usual activities, pain/discomfort and anxiety/
depression.24
Resource use
Health resource use will be captured from routine data
sources (including HES) and from participant self-
report questionnaire. Unit cost data will be obtained
from national databases such as the British National
Formulary and Personal Social Services Research Unit
(PSSRU) Costs of Health and Social Care.
Medication use
We will obtain drug data on trial participants from
general practices for two time periods, before and after
randomisation. Drug classes of interest will include psy-
chotropics and bone protection drugs (bisphosphates
and mineral supplementation). Psychotropic medica-
tions are known to increase risk of falling; this drug
classification includes: antidepressants; psychotropics;
sedatives; hypnotics; anxiolytics and antimanic medica-
tions (as per British National Formulary (BNF) classes
4.1.1–4.3.1). Bisphosphonates, often prescribed with
calcium and vitamin D supplementation, help slow
bone loss and may decrease the risk of fractures (BNF
class 6.6.2).
Drug data collection will be undertaken on a random
sample of general practices, stratified by intervention
arm; drug data will be extracted on all trial participants
within the selected practice. Two periods for drug preva-
lence will be used: (A) baseline: a three calendar month
period prior to month of randomisation, and (B)
follow-up: a 3-month calendar period at 9–12 months
postrandomisation. Drug data will be analysed as
Figure 3 PreFIT Fracture Algorithm. A&E, accident & emergency; CRF, case record form; HES, Hospital Episode Statistics;
ICD, International Classification of Diseases; PreFIT, prevention of falls injury trial.
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number of participants prescribed a psychotropic or
bone protection drugs and change in number of pre-
scribed psychotropics/bone protection drugs by inter-
vention arm.
Sample size
The study has been powered using the proportion of
patients with at least one fracture, although the primary
analysis will be based on a comparison of incidence rate
ratios. This is because the literature offers little informa-
tion to inform the selection of key parameters needed
to estimate the incidence rate ratio including an accur-
ate estimate of the person time denominator and the
coefficient of variation.
In the UK, the annual fracture incidence per 100 men
aged 55–74 years is 2.6 (95% CI 1.9 to 3.3); this rises to
7.6 fractures (95% CI 4.0 to 11.3) per 100 women aged
over 55 years.25 Adjusting for sex differences, the
general estimated annual population-based fracture rate
is 6/100 people (6%) aged over 70 years,26 and this is
the estimate we have selected for the control arm of the
trial. This estimate does not account for repeated
within-individual fractures and hence is a conservative
estimate of the population-based fracture rate.
To have 80% power to detect a statistically (p<0.05)
and clinically relevant, 2% difference in fracture rate for
the main comparisons (advice vs MFFP; advice vs exer-
cise), from 6% to 4% (relative risk reduction, 0.67),
requires 1900 participants per arm, or 5700 participants
overall. Incorporating a design effect to adjust for
varying degrees of modest clustering (ICC set as 0.003),
inflates the sample size estimate to 7800, or 2600 per
arm. Allowing for 15% loss to follow-up, yields a target
sample size of 9000 participants. To recruit 9000 at 150
participants per general practice (range 129–179),
requires 60 general practices to yield a participant
sample range 7740–10 740.
Data analysis
The primary analysis will be by intention to treat. Initial
comparisons will be drawn between advice and the two
active intervention arms, and then if appropriate
between exercise and MFFP. Initial data presentation will
focus on simple descriptive, graphical and tabular sum-
maries as per CONSORT reporting standards for cluster
RCTs, including response to screening, uptake of inter-
ventions and ongoing retention of participants by treat-
ment arm.12 Response rate to postal balance screeners
will be assessed for screening yield. Random effect
Poisson model/negative Binomial model will be used to
assess the primary outcome and will take account of the
18-month outcome data. The data will be analysed using
these models and the fit of the models will be assessed.
The model which provides the best fit will be used to
report the final results, taking account of important pre-
dictors such as deprivation score for GP practice, age,
gender and general practice (random effect). Peripheral
fracture data will be reported using incidence rate (IRR)
and their 95% CI. Likewise, falls data will be analysed
using Poisson or negative Binominal models. We will
undertake analysis to determine the validity of retro-
spective falls reporting collected in the follow-up ques-
tionnaires, against the prospectively collected falls diary
data. We will report and analyse falls data from both
data sources, selecting cross-sectional comparisons for
the randomly sampled, prospectively collected diary data
during each of the discrete time intervals of follow-up.
Time to first fracture will be analysed using survival
analysis methods, accounting for the cluster component.
Similar analyses, as used for the fracture data, will be
computed for the falls data. For other secondary ana-
lyses, linear random effect models will be fitted if the
outcomes are continuous and logistic random effects
models will be fitted if the outcomes are binary. In the
case of no clustering effect, appropriate linear or logistic
models will be used.
Sensitivity analysis will be carried out using imputation
on the primary outcome variable. Multiple imputation,
using the ICE (imputation by chain equations) will be
used to generate the imputation data set. The effect of
the non-compliance in the study will be explored using
complier average causal effect (CACE) or per protocol.
Modelling of CACE may be challenging because of data
distribution. Compliance and adherence will be fully
described outlining the development, content and deliv-
ery of the exercise and MFFP interventions. Briefly,
adherence will be reported as number of sessions
attended; ‘engaged with intervention’ will include those
participants referred for active treatment who attended
at least one treatment session. Further detailed analyses
on adherence to exercise intervention (number of exer-
cise sessions attended with healthcare professional,
number of participants who completed some or all of
the prescribed exercise programme) will be undertaken.
The data monitoring committee will approve the final
version of the data analysis plan.
Planned subgroup analyses
We have selected the following a priori subgroup cri-
teria based on the published literature.27 28 We will
explore effectiveness by age, sex, falls history, cognitive
impairment and frailty. Although we are unlikely to
encounter large numbers of people living in the com-
munity with severe cognitive impairment, the ability to
engage in falls prevention strategies may be affected by
mild to moderate levels of cognitive impairment.
Subgroup effects will be tested through formal inter-
action tests.29
Data security
Participant data are being stored on a secure database in
accordance with the Data Protection Act (1998). A
unique trial identification number is used on all
follow-up questionnaires.
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Data collection and management
Self-reported questionnaire data is scanned using
FORMIC software. This is an automated data capture
package which captures questionnaire text. In addition
to internal FORMIC system validation checks, multiple
external validation checks will be applied: at the point
of receipt of case record form (CRF), on entry scanning
to FORMIC, on transfer from FORMIC into internal
database software and further checks for data outliers
during statistical analysis.
Health economic analysis
Two economic evaluations will be undertaken—a within
trial evaluation will compare the incremental costs per
quality adjusted life year (QALY) at follow-up and,
second, a decision analytic cost-effectiveness model will be
used to estimate the expected incremental cost per
QALY. For both analyses, the perspective will be that of
the UK NHS and social services.
The within trial analysis will use the EQ-5D.30 31 The
costs of delivering MFFP are greater than exercise; there-
fore MFFP will have to prove more effective than exer-
cise to be cost-effective, that is, superior. Costs and
outcomes will be discounted at 3.5% per annum and
probabilistic sensitivity analysis will be undertaken using
the non-parametric bootstrap. The decision analytic cost-
effectiveness analysis model will use a lifetime time
horizon to capture the full impact of any mortality dif-
ferences on the long-term cost-effectiveness. The
methods for estimating health-related quality of life and
discounting will be the same as for the within trial ana-
lysis. Probabilistic sensitivity analyses will be undertaken
using Monte Carlo simulation techniques.
Trial monitoring
A TSC and independent data monitoring committee
(iDMC) will monitor the trial at least every 12 months.
One of the aims of the pilot study was to investigate
whether the trial would fit within a futility framework.
After extensive exploration and consideration of the dif-
ferent aspects of statistical and practical futility, a deci-
sion was undertaken, with the iDMC and TSC to
proceed to the main trial without interim analysis of
fracture rates.
Adverse event management
A safety reporting protocol has been developed for
related and unexpected serious adverse events (AEs)
and directly attributable AEs. An AE is defined as any
untoward medical occurrence in a subject which does
not necessarily have a causal relationship with treatment.
The trial chief investigator will determine whether AEs
require reporting to the trial sponsor, iDMC and Ethics
Committee, in accordance with the safety reporting
protocol.
Ethical issues
The study protocol has approval from the National
Research Ethics Service (REC reference 10/H0401/36;
V.3.1 21/05/2013; see online supplementary material).
Regional and site-specific approvals have been obtained
from NHS Research and Development offices. A
number of ethical issues were addressed in relation to
the trial design. First, consent to cluster randomisation:
general practices consent to randomisation, to
approach potential participants for invitation and
consent to provide the intervention as allocated.
Second, individual consent is obtained for the interven-
tion for recommended interventions as part of usual
clinical care and follows best practice guidance on
consent to treatment. Third, participation in research
assessments and access to patient records: individual
consent is obtained for access to medical records, for
postal and telephone follow-up. We have involved rele-
vant user groups and patient public representatives to
inform the design and implementation of the trial.
Approval was granted by the Derbyshire Research
Ethics Committee.
The study team is committed to full disclosure of the
results of the trial. We will adhere to defined authorship
criteria as per the International Committee of Medical
Journal Editors. The funder will take no role in the ana-
lysis or interpretation of results.
DISCUSSION
This will be the first ever large-scale multicentre clinical
trial to record fracture as the primary outcome in a falls
prevention study comparing advice only, versus MFFP
and exercise in community-dwelling older adults. The
cluster trial design where the clusters are assembled
prior to randomisation provides methodological rigour
and the ability to track uptake and effectiveness at dif-
ferent stages of the intervention. We have used several
novel strategies to maximise the efficiency of the design,
including control of the cluster size through random
sampling, and the use of random subsampling to
reduce the burden of follow-up for outcome measures
that do not require as much statistical power for defini-
tive analysis. The large sample size and multiple
approaches to accurate capture of fractures and falls will
allow considered analyses of primary outcomes and
useful secondary analyses of moderator and mediator
variables.
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